After the Kefauver Harris Amendment was passed in 1962, the . FDA began the DESI review process to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards, including Dianabol.  In 1965, the FDA pressured CIBA to further document its legitimate medical uses, and re-approved the drug for treating post-menopausal osteoporosis and pituitary-deficient dwarfism .  After CIBA's patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the .
The mean oral bioavailability of finasteride is approximately 65%.  Its volume of distribution is 76 L/kg.  The plasma protein binding of finasteride is 90%.  The drug has been found to cross the blood–brain barrier , whereas levels in semen were found to be undetectable.  Finasteride is extensively metabolized in the liver , first by hydroxylation via CYP3A4 and then by aldehyde dehydrogenase .  The metabolites of finasteride have about 20% of its potency in inhibiting 5α-reductase and hence its metabolites are not particularly active.  The drug has a terminal half-life of 5 to 6 hours in adult men (18–60 years of age) and a terminal half-life of 8 hours or more in elderly men (greater than 70 years of age).  It is eliminated as its metabolites 57% in the feces and 40% in the urine . 
The weak androgen oxandrolone (Ox) increases height gain in growth-hormone (GH) treated girls with Turner syndrome (TS), but may also give rise to virilizing side effects. To assess the effect of Ox, at a conventional and low dosage, on behavior, aggression, romantic and sexual interest, mood, and gender role in GH-treated girls with TS, a randomized, placebo-controlled, double-blind study was conducted. 133 patients were treated with GH ( mg/m(2)/d) from baseline, combined with placebo (Pl), Ox mg/kg/d, or Ox mg/kg/d from the age of eight, and with estrogens from the age of 12. The child behavior checklist (CBCL), Junior Dutch Personality Questionnaire (DPQ-J), State-subscale of the Spielberger's State-Trait Anger Scale, Romantic and Sexual Interest Questionnaire, Mood Questionnaire, and Gender Role Questionnaire were filled out before, during, and after discontinuing Ox/Pl. The changes during Ox/Pl therapy were not significantly different between the dosage groups. In untreated patients, the mean CBCL total (P=) and internalizing (P=) T scores, as well as the mean DPQ-J social inadequacy SD score (SDS) (P=) were higher than in reference girls, but decreased during GH+Ox/Pl therapy (P<, P=, P<, respectively). Whereas the mean total (P=) and internalizing (P<) T score remained relatively high, the mean social inadequacy SDS became comparable with reference values. We conclude that in GH-treated girls with TS, Ox mg/kg/d or mg/kg/d does not cause evident psychological virilizing side effects. Problem behavior, frequently present in untreated girls with TS, decreases during therapy, but total and internalizing problem behavior remain increased.